WHO Panel Issues Strong Advice Against Hydroxychloroquine Fo
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The drug hydroxychloroquine, should not be used to prevent COVID-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said. The anti-inflammatory drug should not be used in the fight against the pandemic and is not worthwhile exploring in further research studies of possible COVID-19 treatments.

This strong recommendation, the experts said, is based on high-certainty evidence from six randomized controlled trials involving more than 6,000 participants both with and without known exposure to COVID-19. Former U.S. President Trump said last March that hydroxychloroquine could be a game-changer in the coronavirus pandemic.

He also said he was taking it himself, even after the U.S. medicines regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven. But the WHO's experts said they now judged that almost all people would not consider this drug worthwhile.

The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent COVID-19. The WHO noted in a statement that the recommendation is a so-called living guideline on potential drugs for COVID-19.

The guidelines, which can be updated as new evidence emerges, are designed to advise doctors and healthcare providers on managing respiratory disease and help them make better decisions for patients.